Drug Name:
SLOW FE PLUS FOLIC ACID OTC
Generic Name and Formulations:
Iron, elemental 50mg (as ferrous sulfate 160mg), folic acid 0.4mg; sust-rel tabs.
Company:
Novartis Consumer Health
Therapeutic Use:
Indications for SLOW FE PLUS FOLIC ACID:
Iron deficiency and iron deficiency anemias.
Adult:
Swallow whole. 1–2 tabs daily.
Children:
Not recommended.
Contraindications:
Hemochromatosis. Hemosiderosis.
Warnings/Precautions:
Hepatitis. Pancreatitis. Peptic ulcer or GI inflammation. Achlorhydria. Monitor hematocrit. Folic acid may mask pernicious anemia. Repeated blood transfusions. Elderly.
See Also:
Interactions:
Inhibits tetracycline absorption.
Adverse Reactions:
Nausea, abdominal discomfort and pain, constipation, diarrhea, masks occult bleeding, black stools.
How Supplied:
Slow Fe—30, 60, 90; Plus folic acid—20
Sign Up for Free e-newsletters
ONA Articles
- Real World Results May Not Mirror Clinical Study Outcomes in Multiple Myeloma
- Is Radioimmunotherapy a Path Forward for Melanoma?
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Seeking Reliable Information on Herbal Products
- Adding Bevacizumab to First-line Chemotherapy Benefits Selects Cases of Ovarian Cancer
- Assessing Direct Costs of Treatment-Related Adverse Events in Advanced Melanoma
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- Health Domains May Mediate Psychological Risk in Survivors of Childhood Leukemia
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |